Legal experts are predicting that patents on branded drugs will become more vulnerable to generic competitors in the wake of a recent Supreme Court ruling limiting patent protection for combination products. The case in question involved a patent held by Teleflex Inc that combined 2 previously existing inventions: an adjustable pedal and an electronic throttle control. The Supreme Court invalidated the patent, reasoning that the combination of 2 existing products was too ?obvious? to justify fresh patent protection.
Branded drug manufacturers often seek to extend the patent life of their top-selling drugs by combining them with additional ingredients?a strategy that may become legally problematic in view of the Teleflex decision. In ruling on that case, the high court said that ?granting patent protection to advances that would occur in the ordinary course without real innovation retards progress and may, for patents combining previously known elements, deprive prior inventions of their value or utility.?
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs